Download PDF
Pharmacopsychiatry 2020; 53(04): 174-178
DOI: 10.1055/a-0863-4692
Original Paper

Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?

Mikayla Fan
1   Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
,
Chad A. Bousman
2   Department of Medical Genetics, Psychiatry, Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada
3   Alberta Children’s Hospital Research Institute, Calgary, AB, Canada
4   Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction Expert groups have created dosing guidelines to facilitate the implementation of pharmacogenetic knowledge into clinical practice and commercial pharmacogenetic tests are becoming increasingly accessible. However, the extent to which these commercial tests facilitate the implementation of dosing guidelines is not clear.

Methods Gene-drug pairs included on 22 commercial pharmacogenetic test panels were extracted and cross-referenced with the 74 gene-drug pairs with dosing guidelines in the Pharmacogenetics Knowledgebase, with particular attention given to the 28 gene-drug pairs relevant to psychiatry.

Results On average, 70% of the 28 gene-drug pairs most relevant to psychiatry were covered by the examined tests. Six gene-drug pairs (CYP2D6-venlafaxine, CYP2D6-paroxetine, CYP2D6-amitriptyline, CYP2C19-sertraline, CYP2C19-citalopram, CYP2C19-amitriptyline) were included by all tests. Gene-drug pairs included on less than half of the test panels included HLA-B-phenytoin (14%), HLA-A-carbamazepine (24%), HLA-B-carbamazepine (29%), and CYP2D6-zuclopenthixol (43%).

Discussion Most commercial pharmacogenetic tests we examined are well-equipped to facilitate implementation of the majority of dosing guidelines relevant to psychiatry but are limited in their ability to facilitate implementation of the full spectrum of dosing guidelines currently available.

Key words

decision support tools - gene-drug interaction - translation

Supplementary Material



Publication History

Received: 07 November 2018
Received: 07 February 2019

Accepted: 15 February 2019

Article published online:
21 March 2019

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: From bench to byte–an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673
    Google Scholar
  • 2 Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011; 89: 464-467
    Google Scholar
  • 3 Ross CJ, Visscher H, Sistonen J. et al. The Canadian Pharmacogenomics Network for Drug Safety: A model for safety pharmacology. Thyroid 2010; 20: 681-687
    CrossrefPubMedGoogle Scholar
  • 4 Haga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff 2018; 37: 717-723
    CrossrefPubMedGoogle Scholar
  • 5 Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet Genomics 2017; 27: 387-393
    CrossrefPubMedGoogle Scholar
  • 6 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3: 585-590
    CrossrefPubMedGoogle Scholar
  • 7 Whirl-Carrillo M, McDonagh EM, Hebert JM. et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414-417
    CrossrefPubMedGoogle Scholar
  • 8 Aminkeng F, Ross CJ, Rassekh SR. et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol 2016; 82: 683-695
    CrossrefPubMedGoogle Scholar
  • 9 Clancy JP, Johnson SG, Yee SW. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther 2014; 95: 592-597
    PubMedGoogle Scholar
  • 10 Relling MV, McDonagh EM, Chang T. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 2014; 96: 169-174
    PubMedGoogle Scholar
  • 11 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2016; 102: 37-44
    PubMedGoogle Scholar
  • 12 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
    PubMedGoogle Scholar
  • 13 Bousman C, Dunlop B. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 2018; 18: 613-622
    CrossrefPubMedGoogle Scholar
  • 14 Duong TA, Valeyrie-Allanore L, Wolkenstein P. et al. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390: 1996-2011
    CrossrefPubMedGoogle Scholar